Articular Cartilage Defect

7

Review clinical trials related to Articular Cartilage Defect. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Participants needed: 45
Trial details
Phase: Phase 3Age: 10-17Biological sex: AllType: InterventionalSponsor: Vericel CorporationUpdated: Jun 24, 2026Locations: 12
Eligibility criteria

Symptomatic cartilage or osteochondral defects [+3]

At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the troc... [+21]

Status: Recruiting

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.

Participants needed: 309
Trial details
Phase: Phase 3Age: 17-65Biological sex: AllType: InterventionalSponsor: Vericel CorporationUpdated: May 27, 2026Locations: 4
Eligibility criteria

Age 17 to 65 at the time of planned randomization visit (Visit 2). [+7]

Lesions with an underlying bony defect depth of > 5 mm. [+19]

Status: Not yet recruiting

Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee

The major objective of this study is to evaluate the efficacy of the MACT versus the AMT for the treatment of large cartilage defects in patellofemoral and femorotibial injuries.

Participants needed: 80
Trial details
Age: 15-50Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Universitaire VaudoisUpdated: Mar 12, 2026Locations: 2
Eligibility criteria

Patients aged between 15-50 years [+5]

All inflammatory and synovial pathologies [+10]

Status: Recruiting

Introduction of ACI for Cartilage Repair

This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.

Participants needed: 218
Trial details
Age: 15-50Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Universitaire VaudoisUpdated: Mar 11, 2026Locations: 1
Eligibility criteria

Age between 15 and 50. [+3]

Body mass index (BMI) of 35 or more [+9]

Status: Recruiting

AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip

This is a pilot multi-centre RCT of 40 patients (ages 18-55 years, inclusive) undergoing primary hip arthroscopy with a focal articular cartilage defect of the acetabulum to compare the effect of using autologous matrix-induced chondrogenesis (AMIC) in comparison to microfracture on hip function, health-related quality of life, hip pain, cartilage regeneration, health utility, and any adverse events at 2 years. Follow-up will occur at 6 weeks, 6 months, 12 months, 18 months, and 24 months post-surgery.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: McMaster UniversityUpdated: Sep 24, 2025Locations: 1
Eligibility criteria

All patients aged 18-55 years [+6]

Cartilage defects of the femoral head [+18]

Status: Recruiting

Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions

The goal of this clinical trial is to evaluate the effectiveness and safety of autologous costal osteochondral transplantation in the treatment of Hepple Stage V talar osteochondral lesions, compared with autologous osteoperiosteal transplantation. The main question it aims to answer is: • Whether autologous costal osteochondral transplantation can achieve better clinical outcomes and cartilage repair quality with lower donor site morbidity than autologous osteoperiosteal transplantation in the treatment of Hepple Stage V talar osteochondral lesions. Participants will be randomly assigned to the intervention group (undergoing autologous costal osteochondral transplantation) or the control group (undergoing autologous osteoperiosteal transplantation). Both groups of participants will receive the same postoperative rehabilitation process and follow-up evaluation.

Participants needed: 50
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: The Third Affiliated Hospital of Southern Medical UniversityUpdated: Sep 6, 2023Locations: 1
Eligibility criteria

Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm... [+3]

Combined with lower limb deformity. [+5]

Status: Recruiting

Phase 2 Clinical Trial of CartiLife® in the United States

To evaluate the safety and efficacy of implanting pellet-type extracellular matrix-associated autologous chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the subject with articular cartilage defects of the knee as a result of trauma or degeneration.

Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Biosolution Co., Ltd.Updated: Aug 28, 2023Locations: 5
Eligibility criteria

Male or female subjects aged over 18 at the time of signing the Informed Consent... [+11]

Subject who has inflammatory articular diseases such as rheumatoid arthritis or... [+22]